Pura Vida Investments Llc Decreased Axogen (AXGN) Stake By $3.09 Billion; Cambrex (CBM)’s Sentiment Is 1.58

February 16, 2018 - By Migdalia James

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.75 billion. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 17.36 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Pura Vida Investments Llc decreased Axogen Inc (NASDAQ:AXGN) stake by 47.66% reported in 2017Q4 SEC filing. Pura Vida Investments Llc sold 109,278 shares as Axogen Inc (NASDAQ:AXGN)’s stock rose 35.94%. The Pura Vida Investments Llc holds 120,000 shares with $3.40 billion value, down from 229,278 last quarter. Axogen Inc now has $930.76 million valuation. The stock decreased 0.36% or $0.1 during the last trading session, reaching $27.3. About 130,636 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since February 16, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $838,217 activity.

The stock increased 0.47% or $0.25 during the last trading session, reaching $53.15. About 136,981 shares traded. Cambrex Corporation (CBM) has risen 11.15% since February 16, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Ranger Investment Management L.P. holds 2.91% of its portfolio in Cambrex Corporation for 704,978 shares. Zpr Investment Management owns 34,205 shares or 2.85% of their US portfolio. Moreover, Jw Asset Management Llc has 2.04% invested in the company for 50,519 shares. The New York-based American Capital Management Inc has invested 1.94% in the stock. Neumeier Poma Investment Counsel Llc, a California-based fund reported 335,675 shares.

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, August 28 by Wedbush. Wedbush maintained it with “Buy” rating and $27.0 target in Tuesday, November 21 report. Lake Street downgraded it to “Hold” rating and $9 target in Thursday, November 3 report. On Monday, August 21 the stock rating was maintained by Cantor Fitzgerald with “Buy”. As per Tuesday, November 22, the company rating was upgraded by Lake Street. The firm has “Outperform” rating by Leerink Swann given on Thursday, November 2. The firm earned “Hold” rating on Tuesday, August 11 by Zacks. Leerink Swann maintained AxoGen, Inc. (NASDAQ:AXGN) on Tuesday, November 21 with “Outperform” rating. On Monday, September 11 the stock rating was maintained by Roth Capital with “Buy”. On Monday, November 7 the stock rating was maintained by Wedbush with “Outperform”.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $930.76 million. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Pura Vida Investments Llc is a New York-based institutional investor with more than $223.00 million AUM in October, 2014. Taken from Pura Vida Investments latest Adv, the fund reported to have 13 full and part-time employees. Among which 9 performing investment advisory and research functions. The institutional investor had between 1-10 clients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: